Pharmafile Logo

News and Press Releases

ViroCell signs manufacturing services agreement with UCL to accelerate research into prevention of relapse in childhood blood cancer

Agreement will leverage ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia 12 December 2023 -- London, UK and...

Category: BioManufacturing
Posted: December 12, 2023

ViroCell Biologics
info@virocell.com

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers

At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...

Category: Clinical Trials
Posted: December 12, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023

23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific...

Category: Clinical Trials
Posted: October 23, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer

First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...

Category: Pharmaceutical
Posted: October 9, 2023

Gilead Sciences, Inc